Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hamid Emamekhoo

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|April 9, 2025
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025Timothy Gilligan, Daniel W Lin, Nabil Adra, et al.
Urologic Oncology|October 28, 2025
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE studyTanya Jindal, Cindy Y Jiang, Omar Alhalabi, et al.
Cancer|December 9, 2021
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) studyVadim S Koshkin, Nicholas Henderson, Marihella James, et al.
The Oncologist|October 7, 2025
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative studyCindy Y Jiang, Hyunsoo Hwang, Ilana Y Epstein, et al.
Clinical Genitourinary Cancer|February 5, 2026
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE DatabaseAlbert Jang, Tanya Jindal, Ali Raza Khaki, et al.
European Urology|September 15, 2025
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE StudyTanya Jindal, Cindy Y Jiang, Omar Alhalabi, et al.
The Journal of Clinical Investigation|November 1, 2022
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancerShuang G Zhao, Jamie M Sperger, Jennifer L Schehr, et al.
Cancer Discovery|April 1, 2025
High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical OutcomesMarina N Sharifi, Jamie M Sperger, Amy K Taylor, et al.
Cancer Medicine|October 1, 2025
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE StudyAmanda Nizam, Charles B Nguyen, Jinju Li, et al.
Cancer Discovery|February 6, 2025
High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomesMarina N Sharifi, Jamie M Sperger, Amy K Taylor, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Journal of the National Comprehensive Cancer Network : JNCCN|April 9, 2025
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025Timothy Gilligan, Daniel W Lin, Nabil Adra, et al.
Urologic Oncology|October 28, 2025
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE studyTanya Jindal, Cindy Y Jiang, Omar Alhalabi, et al.
Cancer|December 9, 2021
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) studyVadim S Koshkin, Nicholas Henderson, Marihella James, et al.
The Oncologist|October 7, 2025
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative studyCindy Y Jiang, Hyunsoo Hwang, Ilana Y Epstein, et al.
Clinical Genitourinary Cancer|February 5, 2026
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE DatabaseAlbert Jang, Tanya Jindal, Ali Raza Khaki, et al.
European Urology|September 15, 2025
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE StudyTanya Jindal, Cindy Y Jiang, Omar Alhalabi, et al.
The Journal of Clinical Investigation|November 1, 2022
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancerShuang G Zhao, Jamie M Sperger, Jennifer L Schehr, et al.
Cancer Discovery|April 1, 2025
High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical OutcomesMarina N Sharifi, Jamie M Sperger, Amy K Taylor, et al.
Cancer Medicine|October 1, 2025
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE StudyAmanda Nizam, Charles B Nguyen, Jinju Li, et al.
Cancer Discovery|February 6, 2025
High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomesMarina N Sharifi, Jamie M Sperger, Amy K Taylor, et al.
Pageof 7